|
Dr. Bebbington has over 18 years of experience in the biotechnology industry, particularly in antibody expression technology and drug discovery for immune-based diseases. He worked for 14 years at Celltech where he developed the glutamine synthetase (GS) gene amplification system for the efficient production of recombinant antibodies in mammalian cell systems. This technology has led to antibody production yields of 1g/L at large scale. In 1999, Dr. Bebbington joined Coulter Pharmaceutical and led the California research group of Corixa following the merger of Coulter Pharmaceutical with Corixa. He led the team that generated an engineered human antibody to the type I interferon receptor and obtained the preclinical data necessary to support the clinical development of this antibody for the treatment of several autoimmune diseases. | 